Target Nanoparticles against Pancreatic Cancer: Fewer Side Effects in Therapy
Pancreatic cancer is the most common lethal tumor in America. This lethality is related to limited treatment options. Conventional treatments involve the non-specific use of chemotherapeutical agents such as 5-FU, capecitabine, gemcitabine, paclitaxel, cisplatin, oxaliplatin, or irinotecan, which pr...
Guardado en:
Autores principales: | Jorge A. Roacho-Pérez, Elsa N. Garza-Treviño, Paulina Delgado-Gonzalez, Zuca G-Buentello, Juan Luis Delgado-Gallegos, Christian Chapa-Gonzalez, Margarita Sánchez-Domínguez, Celia N. Sánchez-Domínguez, Jose Francisco Islas |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/205d352e61ba491d8955bb9be25ba703 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Risk factors for pancreatitis and pancreatic cancer
por: Irina N. Grigor’eva, et al.
Publicado: (2021) -
Nanoparticle-based hyperthermia distinctly impacts production of ROS, expression of Ki-67, TOP2A, and TPX2, and induction of apoptosis in pancreatic cancer
por: Ludwig R, et al.
Publicado: (2017) -
Knockdown of ZFR suppresses cell proliferation and invasion of human pancreatic cancer
por: Zhao,Xiaolan, et al.
Publicado: (2016) -
Epidermal Growth Factor Receptor and Its Role in Pancreatic Cancer Treatment Mediated by Nanoparticles
por: Grapa CM, et al.
Publicado: (2019) -
Pancreatitis aguda recurrente, caso clínico
por: ARGOLLO M,PAMELA, et al.
Publicado: (2007)